{"prompt": "['APPROVED RPCI IRB', '3/22/2021', 'ROSWELL', 'PARK', 'CANCER INSTITUTE', 'TITLE: A Randomized Multicenter Phase II Study Using 2-1|Hexyloxyethyl|-2-', 'Devinylpyropheophorbide-A (HPPH) with PDT versus Standard of Care Surgery for', 'Patients with T1/T2 NO Squamous Cell Carcinoma of the Oral Cavity', 'Roswell Park Cancer Institute', 'Study Number: I 33616', 'NCT03090412', 'Initial Date: 15 July 2016', 'Amendment 1: 21 February 2017', 'Amendment 2: 5 June 2017', 'Amendment 3:', '22 August 2019', 'Amendment 4:', '14 January 2021', 'IND Holder: Roswell Park Cancer Institute', 'Principal Investigator:', 'Jon Chan MD', 'Roswell Park Cancer Institute', 'Elm & Carlton Streets', 'Buffalo, New York 14263', '716-845-3158', 'Jon.Chan@RoswellPark.org', 'Sponsor: Roswell Park Cancer Institute', 'Industry Supporter: Photolitec LLC', 'Confidentiality Statement', 'Any and all information presented in this document shall be treated as confidential and shall', 'remain the exclusive property of the party(ies) mentioned above. The use of such', 'confidential information must be restricted to the recipient for the agreed purpose and must', 'not be disclosed, published, or otherwise communicated to any unauthorized persons, for', 'any reason, in any form whatsoever without the prior written consent of the party(ies)', 'above.', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 1 of 64']['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', 'RPCI Study Contacts', 'FOR NETWORK SITES: Please contact the RPCI Network Monitor for any study-related', 'questions regarding sample handling, processing or shipping.', 'Study Personnel outside of RPCI-CRS who will be housing essential documents or', 'receiving, analyzing or storing biological samples.', 'Name', 'Institution', 'Email', 'Role', 'Gal Shafirstein, DSc', 'Roswell Park Cancer', 'Gal.Shafirstein@RoswellPark.org', 'Treatment Planning', 'Institute, Buffalo, NY', 'Sandra Gollnick, PhD', 'Roswell Park Cancer', 'andra.Gollnick@RoswellPark.org', 'Institute, Buffalo, NY', 'David Bellnier, PhD', 'Roswell Park Cancer', 'David.Bellnier@RoswellPark.org', 'Drug uptake', 'Institute, Buffalo, NY', 'Alan Hutson, PhD', 'Roswell Park Cancer', 'Alan.Hutson@RoswellPark.org', 'Statistical Analysis', 'Institute, Buffalo, NY', 'Joseph D.', 'Roswell Park Cancer', 'joseph.tario@RoswellPark.org', 'Flow Cytometry', 'Tario,Jr. PhD', 'Institute, Buffalo, NY', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 2 of 64']['APPROVED RPCI IRB', '3/22/2021', 'Roswell Park Protocol No.: I 33616', 'SYNOPSIS', 'A Randomized Multicenter Phase II Study Using 2-1[Hexyloxyethyl]-2-', 'Title / Phase', 'Devinylpyropheophorbide-A (HPPH) with PDT versus Standard of Care Surgery for', 'Patients with T1/T2 NO Squamous Cell Carcinoma of the Oral Cavity', 'Roswell Park Cancer', 'Institute Study', 'I 33616', 'Number', 'Roswell Park Cancer', 'Jon Chan, MD', 'Institute Investigator', 'Sponsor', 'Roswell Park Cancer Institute', 'Industry Supporter', 'Photolitec LLC', 'Study Drug', 'HPPH (2-1[hexyloxyethyl]-2-devinylpyropheophorbide-a)', 'Primary:', 'To test the non-inferiority of PDT to standard of care surgery by comparing the', 'rate of tumor response after PDT to those observed after surgery, at 24 months', 'post treatment.', 'Secondary:', 'To determine quality of life (QoL) at 6, 12, 18, and 24 months post PDT or', 'Objectives', 'surgery.', 'To assess the toxicity using the CTEP NCI Common Terminology Criteria for', 'Adverse Events (CTCAE Version 4.0).', 'Tertiary:', 'Immune markers (T cells).', 'To investigate the correlation of diffuse reflectance optical spectroscopy with', 'tumor response to PDT (Appendix B).', 'This is an open-label, randomized, multicenter Phase II study of HPPH-mediated', 'PDT in patients with lesions that are diagnosed as previously untreated T1 NO or', 'T2 NO SCC of the oral cavity. 114 participants will be randomized (1:1) to surgery', '(57) or PDT with HPPH (57). The randomization will be done at RPCI by the', 'biostatistician.', 'Participants will be treated on an outpatient basis. Rarely, participants may require', 'hospitalization, but this will be decided on a case by case basis. All participants', 'will meet the inclusion and exclusion criteria.', 'Participants randomized to PDT with HPPH will be administered a single dose of', 'Study Design', 'HPPH at 4 mg/m\u00b2 via slow intravenous (IV) infusion over 1 hour. Approximately', '1 day later, the target tumor will be illuminated with a 665-nm laser light at dose', 'of 140 Joules/cm\u00b2 delivered at a fluence rate of 150 mW/cm\u00b2. The participants', 'will be scheduled to have clinical examination at 1 week, 4 - 6 weeks, 12-16', 'weeks, and at 24 months post therapy. Pathological evaluation will be conducted', 'by taking a 3-mm punch biopsy from the treated region during the 12-16 weeks', 'clinical visit. In the event that a suspicious lesion is observed, the participants will', 'be scheduled for a biopsy at the discretion of the treating physician. Participants', 'will receive standard curative therapy 6 weeks after failing to respond to PDT with', 'HPPH. Tumor response will be determined according to the revised response', 'evaluation criteria in solid tumors (RECIST v1.1).', 'PRIVATE AND CONFIDENTIAL INFORMATION OF ROSWELL PARK CANCER INSTITUTE', '01-14-21', 'Page 3 of 64']\n\n###\n\n", "completion": "END"}